Semaglutide TFA is a agonist of glucagon-like peptide-1 (GLP-1) receptor,with a potential for type 2 diabetes treatment.

Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. Semaglutide`s GLP-1R affinity is 0.38±0.06 nM[1]. Semaglutide is an analogue of GLP-1 with 94% sequence omology to human GLP-1[3.

The plasma half-life of Semaglutide is 46h in mini-pigs following i.v. administration and semaglutide has an MRT of 63.6h after s.c. dosing to mini-pigs[1]. 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced motor impairmentsimproved by Semaglutide. In addition, Semaglutide rescues the decrease of tyrosine hydroxylase (TH) levels, reduces lipid peroxidation, alleviates the inflammation response, inhibits the apoptosis pathway and increases autophagy- related protein expression, to protect dopaminergic neurons in the substantia nigra and striatum. Moreover, the long-acting GLP-1 analogue semaglutide is superior to liraglutide in most parameters[2]. Semaglutide lowers blood glucose by stimulating the release of insulin and also lowers body weight[3].